BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Serguera C, Bemelmans AP. Gene therapy of the central nervous system: general considerations on viral vectors for gene transfer into the brain. Rev Neurol (Paris) 2014;170:727-38. [PMID: 25459120 DOI: 10.1016/j.neurol.2014.09.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Du X, Yin M, Yuan L, Zhang G, Fan Y, Li Z, Yuan N, Lv X, Zhao X, Zou S, Deng W, Kosten TR, Zhang XY. Reduction of depression-like behavior in rat model induced by ShRNA targeting norepinephrine transporter in locus coeruleus. Transl Psychiatry 2020;10:130. [PMID: 32366842 DOI: 10.1038/s41398-020-0808-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
2 Ravi B, Antonellis A, Sumner CJ, Lieberman AP. Genetic approaches to the treatment of inherited neuromuscular diseases. Hum Mol Genet 2019;28:R55-64. [PMID: 31227836 DOI: 10.1093/hmg/ddz131] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
3 Islam MA, Firdous J, Badruddoza AZM, Reesor E, Azad M, Hasan A, Lim M, Cao W, Guillemette S, Cho CS. M cell targeting engineered biomaterials for effective vaccination. Biomaterials 2019;192:75-94. [PMID: 30439573 DOI: 10.1016/j.biomaterials.2018.10.041] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
4 Sumner CJ, Crawford TO. Two breakthrough gene-targeted treatments for spinal muscular atrophy: challenges remain. J Clin Invest. 2018;128:3219-3227. [PMID: 29985170 DOI: 10.1172/jci121658] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 12.0] [Reference Citation Analysis]
5 Geetha Bai R, Ninan N, Muthoosamy K, Manickam S. Graphene: A versatile platform for nanotheranostics and tissue engineering. Progress in Materials Science 2018;91:24-69. [DOI: 10.1016/j.pmatsci.2017.08.004] [Cited by in Crossref: 82] [Cited by in F6Publishing: 64] [Article Influence: 20.5] [Reference Citation Analysis]
6 Arsenault J, Gholizadeh S, Niibori Y, Pacey LK, Halder SK, Koxhioni E, Konno A, Hirai H, Hampson DR. FMRP Expression Levels in Mouse Central Nervous System Neurons Determine Behavioral Phenotype. Hum Gene Ther 2016;27:982-96. [PMID: 27604541 DOI: 10.1089/hum.2016.090] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
7 Garanina EE, Mukhamedshina YO, Salafutdinov II, Kiyasov AP, Lima LM, Reis HJ, Palotás A, Islamov RR, Rizvanov AA. Construction of recombinant adenovirus containing picorna-viral 2A-peptide sequence for the co-expression of neuro-protective growth factors in human umbilical cord blood cells. Spinal Cord 2016;54:423-30. [PMID: 26439843 DOI: 10.1038/sc.2015.162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
8 Blum K, Thanos PK, Badgaiyan RD, Febo M, Oscar-Berman M, Fratantonio J, Demotrovics Z, Gold MS. Neurogenetics and gene therapy for reward deficiency syndrome: are we going to the Promised Land? Expert Opin Biol Ther 2015;15:973-85. [PMID: 25974314 DOI: 10.1517/14712598.2015.1045871] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]